Publication:
Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease

Simple item page
dc.contributor.authorKEKLİKKIRAN, ÇAĞLAYAN
dc.contributor.authorsKani, Haluk Tarik; Demirtas, Coskun Ozer; Keklikkiran, Caglayan; Ergenc, Ilkay; Mehdiyev, Shahin; Akdeniz, Esra; Yilmaz, Yusuf
dc.date.accessioned2022-03-12T22:55:10Z
dc.date.available2022-03-12T22:55:10Z
dc.date.issued2021
dc.description.abstractBackground: Metabolic syndrome (MS) is a condition that consists of several disorders, and the individual impact of these disorders on metabolic dysfunction-associated fatty liver disease (MAFLD) is still not clear in a combined diagnosis of MS. In this study, we aimed to investigate the effect of MS on advanced fibrosis in patients with MAFLD. Methods: We recruited the patients from our gastroenterology out-patient clinic who were being followed up for MAFLD. MAFLD was diagnosed with liver biopsy in all patients. The frequency of MS and other metabolic parameters were also compared between groups with advanced fibrosis and groups in which fibrosis was not as advanced. Results: In total, we enrolled 424 biopsy-proven MAFLD patients to the study. In univariate analysis, individuals with greater age, body mass index (BMI), higher aspartate transaminase (AST), MS, impaired fasting glucose, hypertension, enlarged waist circumference (WC), diabetes mellitus (DM), and women had significantly increased risk for fibrosis. In multivariate analysis, it was found that DM, greater age, higher BMI, and increased AST were seen more commonly in MAFLD patients with advanced fibrosis Conclusion: Greater age, a higher BMI, higher AST and a diagnosis of diabetes were more commonly associated with advanced fibrosis. However, DM was found to be the strongest predictive factor of advanced fibrosis in our cohort (OR: 2.495). Multivariate analyses did not indicate a significantly common occurrence of MS in the advanced fibrosis group, despite its important role in MAFLD pathophysiology.
dc.identifier.doi10.5152/tjg.2021.20512
dc.identifier.eissn2148-5607
dc.identifier.pubmed34528879
dc.identifier.urihttps://hdl.handle.net/11424/236670
dc.identifier.wosWOS:000697285200007
dc.language.isoeng
dc.publisherAVES
dc.relation.ispartofTURKISH JOURNAL OF GASTROENTEROLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectFibrosis
dc.subjectmetabolic syndrome
dc.subjectmetabolic dysfunction-associated fatty liver disease
dc.subjectSEVERITY
dc.subjectSTEATOHEPATITIS
dc.subjectPROGRESSION
dc.subjectOUTCOMES
dc.subjectNAFLD
dc.titleEvaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
dc.typearticle
dspace.entity.typePublication
local.avesis.id5d54144a-96a8-41ee-bd59-1d0638e228bf
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages6
oaire.citation.endPage666
oaire.citation.issue8
oaire.citation.startPage661
oaire.citation.titleTURKISH JOURNAL OF GASTROENTEROLOGY
oaire.citation.volume32
relation.isAuthorOfPublication2e2ea3a8-5476-4a01-9ae7-c31152fdf024
relation.isAuthorOfPublication.latestForDiscovery2e2ea3a8-5476-4a01-9ae7-c31152fdf024

Files

Collections

Research Outputs